<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140572" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Autoimmune Encephalitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gole</surname>
            <given-names>Shrey</given-names>
          </name>
          <aff>Northwestern Medicine McHenry Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Anand</surname>
            <given-names>Amritpal</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shrey Gole declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Amritpal Anand declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>2</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140572.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Autoimmune encephalitis refers to acute to subacute, progressive inflammation of the brain associated with antibodies against neuronal cell surface and synaptic protein, most commonly being anti-N-methyl-D-aspartate<italic toggle="yes">&#x000a0;</italic>receptor encephalitis. It is frequently associated with underlying malignancy and needs appropriate screening. This condition is usually treatment-responsive with immunotherapy and has better outcomes if initiated early in the clinical course. This activity outlines the pathophysiology, clinical presentation, and management of autoimmune encephalitis and reviews the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the epidemiology of autoimmune encephalitis.</p></list-item><list-item><p>Explain the pathophysiology of autoimmune encephalitis.</p></list-item><list-item><p>Outline the typical presentation of a patient with autoimmune encephalitis.</p></list-item><list-item><p>Summarize the management considerations for patients with autoimmune encephalitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140572&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140572">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140572.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Autoimmune encephalitis (AIE) is an immune-mediated condition that induces brain inflammation and is one of the most common causes of non-infectious encephalitis. In the past decade, AIE has become an emerging addition to the differential diagnosis when a classical infection cannot explain focal neurological symptoms. While the exact mechanism of AIE is unknown, current literature suggests that autoimmune antibodies target synaptic proteins, leading to widespread inflammation.<xref ref-type="bibr" rid="article-140572.r1">[1]</xref></p>
        <p>AIE commonly presents as a new onset of memory loss, psychosis, altered mental status, or seizures, with the presentation taking place over a few weeks to three months. AIE involves several parts of the nervous system, including the limbic system, the spinal cord, and/or the entire neuraxis. AIE can be confirmed by multiple modalities, including laboratory testing (antibody detection), neuroimaging, and electrophysiological studies (electroencephalogram).</p>
        <p>Although classical paraneoplastic encephalitis is commonly associated with cancer, AIE may or may not be related. Therefore, once the diagnosis is established, patients should undergo cancer screening due to a high degree of association with underlying malignancy. Although these tests can be time-consuming, clinicians should consider initiating treatment early in the course if their clinical suspicion is high, as they are often treatment-responsive and have significantly improved outcomes. The most commonly studied subtype of AIE is anti-N-methyl-D-aspartate receptor encephalitis, so the management approach is primarily based on that.<xref ref-type="bibr" rid="article-140572.r2">[2]</xref> This review describes the current state of knowledge on various types of autoimmune encephalitis and educates readers with a concise, up-to-date summary.</p>
      </sec>
      <sec id="article-140572.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Although the exact mechanism is currently under investigation,&#x000a0;autoimmune encephalitis is thought to be an autoimmune process with an exaggerated response to a neuronal self-antigen. Unlike paraneoplastic encephalitis, which is a T-cell-mediated response, antibodies in AIE are intrinsically pathogenic. They induce inflammation by targeting specific neuronal proteins. Synaptic proteins, ion channels, and intracellular receptors are the target proteins that have been established so far. When bound to target proteins, these antibodies induce conformational changes that lead to an inflammatory response.</p>
      </sec>
      <sec id="article-140572.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Epidemiological data on autoimmune encephalitis is under-reported due to its variable presentation and numerous antibodies responsible, as described below in&#x000a0;<bold>Table.&#x000a0;</bold>Commonly Reported Antibodies. The incidence of encephalitis reported in adults varies between 0.7 to 12.6 per 100,000&#x000a0;and&#x000a0;has been reported in adult and pediatric populations.<xref ref-type="bibr" rid="article-140572.r3">[3]</xref>&#x000a0;To date, anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis has been commonly reported under AIE, and most studies have been on it. In one large multicentric observational study, 80% of patients with anti-NMDAR encephalitis were female with a median age of disease onset of 21 years. Furthermore, 38% of the population in the study was found to have an underlying neoplasm with a predominance of ovarian teratoma.<xref ref-type="bibr" rid="article-140572.r4">[4]</xref></p>
      </sec>
      <sec id="article-140572.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>To this date, the exact mechanism of the collapse of immune tolerance in AIE largely remains unknown. Cases with AIE often have an infection as a preceding event, causing inflammation leading to neurological symptoms. There have been case reports and observational studies to suggest that herpes simplex virus encephalitis (HSVE) triggers an immune response, causing anti-NMDAR encephalitis.<xref ref-type="bibr" rid="article-140572.r5">[5]</xref>&#x000a0;Also, genetic factors like human leukocyte antigen (HLA) were strongly associated with certain antibody production causing autoimmune responses, eg, IgLON 5 antibody encephalitis.<xref ref-type="bibr" rid="article-140572.r6">[6]</xref></p>
        <table-wrap id="article-140572.table0" position="float" orientation="portrait">
          <caption>
            <title>Table.&#x000a0;Commonly Reported Antibodies&#x000a0;&#x000a0;</title>
          </caption>
          <table style="height: 2216px; width: 793px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr style="height: 26px;">
                <td style="width: 73.464676px; height: 26px;" rowspan="1" colspan="1">
<bold>Auto-antibody</bold>
</td>
                <td style="width: 69.347824px; height: 26px;" rowspan="1" colspan="1">
<bold>Median age of onset</bold>
</td>
                <td style="width: 45.108696px; height: 26px;" rowspan="1" colspan="1">
<bold>Men to women ratio</bold>
</td>
                <td style="width: 224.076096px; height: 26px;" rowspan="1" colspan="1">
<bold>Clinical manifestations</bold>
</td>
                <td style="width: 90.434784px; height: 26px;" rowspan="1" colspan="1">
<bold>Tumor association</bold>
</td>
                <td style="width: 127.309784px; height: 26px;" rowspan="1" colspan="1">
<bold>Response to therapy</bold>
</td>
              </tr>
              <tr style="height: 255px;">
                <td style="width: 73.464676px; height: 255px;" rowspan="1" colspan="1">NMDAR</td>
                <td style="width: 69.347824px; height: 255px;" rowspan="1" colspan="1">&#x000a0;21 (2 months-85 yrs)</td>
                <td style="width: 45.108696px; height: 255px;" rowspan="1" colspan="1">1:4&#x000a0;</td>
                <td style="width: 224.076096px; height: 255px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Prominent neuropsychiatric manifestations</p></list-item><list-item><p>Seizures</p></list-item><list-item><p>Movement disorders</p></list-item><list-item><p>Language disorders</p></list-item><list-item><p>Autonomic dysfunction</p></list-item><list-item><p>Central apnea</p></list-item><list-item><p>Coma</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 255px;" rowspan="1" colspan="1">Ovarian teratoma</td>
                <td style="width: 127.309784px; height: 255px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Almost 53% reported improvement within first 4 weeks from first-line therapy or tumor removal</p></list-item><list-item><p>Almost 80% achieved good outcomes the first 24 months with mRS 0-2</p></list-item><list-item><p>About 10% relapses seen within 2 years</p></list-item><list-item><p>Reduced if treated with IT or tumor removal</p></list-item><list-item><p>5-7% mortality&#x000a0;<xref ref-type="bibr" rid="article-140572.r7">[7]</xref><xref ref-type="bibr" rid="article-140572.r4">[4]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 137px;">
                <td style="width: 73.464676px; height: 137px;" rowspan="1" colspan="1">LG1</td>
                <td style="width: 69.347824px; height: 137px;" rowspan="1" colspan="1">&#x000a0;61 (31-84)</td>
                <td style="width: 45.108696px; height: 137px;" rowspan="1" colspan="1">&#x000a0;2:1</td>
                <td style="width: 224.076096px; height: 137px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Limbic encephalitis</p></list-item><list-item><p>Focal seizures</p></list-item><list-item><p>Hyponatremia</p></list-item><list-item><p>Classical fasciobrachial dystonic seizures</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 137px;" rowspan="1" colspan="1">Thymoma, lung, renal, and thyroid cancer</td>
                <td style="width: 127.309784px; height: 137px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>80% response to IT</p></list-item><list-item><p>Mild cognitive defect at 2 yrs follow-up</p></list-item><list-item><p>Relapses are common (35%)<xref ref-type="bibr" rid="article-140572.r8">[8]</xref><xref ref-type="bibr" rid="article-140572.r9">[9]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 175px;">
                <td style="width: 73.464676px; height: 175px;" rowspan="1" colspan="1">
<p>CASPR2</p>
</td>
                <td style="width: 69.347824px; height: 175px;" rowspan="1" colspan="1">66 (25-77)</td>
                <td style="width: 45.108696px; height: 175px;" rowspan="1" colspan="1">&#x000a0;9:1</td>
                <td style="width: 224.076096px; height: 175px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Limbic encephalitis</p></list-item><list-item><p>Morvan syndrome</p></list-item><list-item><p>Peripheral nerve excitability</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 175px;" rowspan="1" colspan="1">Thymoma</td>
                <td style="width: 127.309784px; height: 175px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Almost 48% had full/good recovery with IT or tumor removal</p></list-item><list-item><p>About 44% had partial recovery with IT</p></list-item><list-item><p>About 25% relapses</p></list-item><list-item><p>Case fatality rate 10% after 2 yrs&#x000a0;<xref ref-type="bibr" rid="article-140572.r10">[10]</xref><xref ref-type="bibr" rid="article-140572.r11">[11]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 66px;">
                <td style="width: 73.464676px; height: 66px;" rowspan="1" colspan="1">GABA-a</td>
                <td style="width: 69.347824px; height: 66px;" rowspan="1" colspan="1">&#x000a0;40 (2.5months-88yrs)</td>
                <td style="width: 45.108696px; height: 66px;" rowspan="1" colspan="1">1:1&#x000a0;</td>
                <td style="width: 224.076096px; height: 66px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Limbic encephalitis</p></list-item><list-item><p>Seizures</p></list-item><list-item><p>Refractory status epilepticus</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 66px;" rowspan="1" colspan="1">Thymoma</td>
                <td style="width: 127.309784px; height: 66px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Substantial improvement( 86%), although mortality with status epilepticus&#x000a0;&#x000a0;reported&#x000a0;<xref ref-type="bibr" rid="article-140572.r12">[12]</xref><xref ref-type="bibr" rid="article-140572.r13">[13]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 66px;">
                <td style="width: 73.464676px; height: 66px;" rowspan="1" colspan="1">GABA-b</td>
                <td style="width: 69.347824px; height: 66px;" rowspan="1" colspan="1">&#x000a0;61 (16-77)</td>
                <td style="width: 45.108696px; height: 66px;" rowspan="1" colspan="1">&#x000a0;1.5:1</td>
                <td style="width: 224.076096px; height: 66px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Limbic encephalitis</p></list-item><list-item><p>Seizures</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 66px;" rowspan="1" colspan="1">Small cell lung carcinoma</td>
                <td style="width: 127.309784px; height: 66px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Neurological response with immunotherapy and cancer treatment (90%)&#x000a0;<xref ref-type="bibr" rid="article-140572.r14">[14]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 80px;">
                <td style="width: 73.464676px; height: 80px;" rowspan="1" colspan="1">AMPA</td>
                <td style="width: 69.347824px; height: 80px;" rowspan="1" colspan="1">&#x000a0;53.1 (14-92)</td>
                <td style="width: 45.108696px; height: 80px;" rowspan="1" colspan="1">&#x000a0;1:2</td>
                <td style="width: 224.076096px; height: 80px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Limbic encephalitis</p></list-item><list-item><p>Confusion</p></list-item><list-item><p>Amnesia</p></list-item><list-item><p>Seizures</p></list-item><list-item><p>Psychiatric complaints&#x000a0;</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 80px;" rowspan="1" colspan="1">Thymus, lung, breast, and ovarian cancers</td>
                <td style="width: 127.309784px; height: 80px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Good response to IT</p></list-item><list-item><p>16% died from complications related to underlying malignancy&#x000a0;<xref ref-type="bibr" rid="article-140572.r15">[15]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 53px;">
                <td style="width: 73.464676px; height: 53px;" rowspan="1" colspan="1">DPPX</td>
                <td style="width: 69.347824px; height: 53px;" rowspan="1" colspan="1">&#x000a0;53 (13-75)</td>
                <td style="width: 45.108696px; height: 53px;" rowspan="1" colspan="1">&#x000a0;1.6:1</td>
                <td style="width: 224.076096px; height: 53px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Multifocal encephalitis</p></list-item><list-item><p>Amnesia</p></list-item><list-item><p>Delirium</p></list-item><list-item><p>Myoclonus</p></list-item><list-item><p>Prominent weight loss and diarrhea</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 53px;" rowspan="1" colspan="1">B-cell neoplasm (gastrointestinal lymphoma and CLL)</td>
                <td style="width: 127.309784px; height: 53px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>&#x000a0;~63% responsive to IT&#x000a0;<xref ref-type="bibr" rid="article-140572.r16">[16]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 139px;">
                <td style="width: 73.464676px; height: 139px;" rowspan="1" colspan="1">Glycine</td>
                <td style="width: 69.347824px; height: 139px;" rowspan="1" colspan="1">50 (1-75)</td>
                <td style="width: 45.108696px; height: 139px;" rowspan="1" colspan="1">&#x000a0; 1:1</td>
                <td style="width: 224.076096px; height: 139px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Stiff person spectrum syndrome</p></list-item><list-item><p>PERM (progressive encephalitis with rigidity and myoclonus)</p></list-item><list-item><p>Encephalitis</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 139px;" rowspan="1" colspan="1">Thymoma, B -cell lymphoma</td>
                <td style="width: 127.309784px; height: 139px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Good response to IT, with median mRS =1 at most recent follow-up.</p></list-item><list-item><p>29% associated with autoimmune disorders (psoriasis, thyroid, diabetes)&#x000a0;<xref ref-type="bibr" rid="article-140572.r17">[17]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 40px;">
                <td style="width: 73.464676px; height: 40px;" rowspan="1" colspan="1">MOG</td>
                <td style="width: 69.347824px; height: 40px;" rowspan="1" colspan="1">&#x000a0;30.5 (15-69)</td>
                <td style="width: 45.108696px; height: 40px;" rowspan="1" colspan="1">&#x000a0;1:1</td>
                <td style="width: 224.076096px; height: 40px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Optic neuritis</p></list-item><list-item><p>Seizures</p></list-item><list-item><p>Encephalitis</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 40px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 127.309784px; height: 40px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Good response to IT</p></list-item><list-item><p>Relapses &#x000a0;common&#x000a0;<xref ref-type="bibr" rid="article-140572.r18">[18]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 66px;">
                <td style="width: 73.464676px; height: 66px;" rowspan="1" colspan="1">Neurexin</td>
                <td style="width: 69.347824px; height: 66px;" rowspan="1" colspan="1">&#x000a0;44 (23&#x02013;57)</td>
                <td style="width: 45.108696px; height: 66px;" rowspan="1" colspan="1">&#x000a0;1:2</td>
                <td style="width: 224.076096px; height: 66px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Prodromal fever</p></list-item><list-item><p>Weight loss</p></list-item><list-item><p>Gastrointestinal symptoms</p></list-item><list-item><p>Confusion</p></list-item><list-item><p>Seizures</p></list-item><list-item><p>Decreased level of consciousness</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 66px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 127.309784px; height: 66px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Partial response to IT (60%)&#x000a0;<xref ref-type="bibr" rid="article-140572.r19">[19]</xref></p></list-item></list>
</td>
              </tr>
              <tr style="height: 106px;">
                <td style="width: 73.464676px; height: 106px;" rowspan="1" colspan="1">IgLON</td>
                <td style="width: 69.347824px; height: 106px;" rowspan="1" colspan="1">&#x000a0;64 (42-81)</td>
                <td style="width: 45.108696px; height: 106px;" rowspan="1" colspan="1">1:1&#x000a0;</td>
                <td style="width: 224.076096px; height: 106px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>Sleep disorders, bulbar dysfunction</p></list-item><list-item><p>Gait abnormalities.</p></list-item><list-item><p>HLADRB1*10:01/HLADQB*05:01 alleles in 87%.</p></list-item></list>
</td>
                <td style="width: 90.434784px; height: 106px;" rowspan="1" colspan="1">&#x000a0;</td>
                <td style="width: 127.309784px; height: 106px;" rowspan="1" colspan="1">
<list list-type="bullet"><list-item><p>43% respond better with combination therapy vs. monotherapy (67 vs 32)</p></list-item><list-item><p>Better with second-line compared to first line (54 vs 33)&#x000a0;<xref ref-type="bibr" rid="article-140572.r6">[6]</xref><xref ref-type="bibr" rid="article-140572.r20">[20]</xref></p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="article-140572.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The initial clinical presentation is vague and non-specific. Also, many patients do not present with common symptoms, so diagnostic modality involving imaging, serology, and EEG remains the mainstay for diagnosing this condition. It varies from typical limbic system involvement to syndromes with complex neuropsychiatric manifestations. There have been specific syndromes associated with particular antibodies. Nonetheless, the presentation in most cases is widely variable.</p>
        <p>Approximately 70% of patients have prodromal manifestations of headache, fever, and other symptoms resembling viral etiology. Then, it progresses with acute to subacute onset of memory deficits, altered mental status, behavior changes, psychosis, orofacial dyskinesia, hallucinations, agitation, delusions, catatonia, seizures, or abnormal movements. These patients may have a fluctuating clinical course with interval improvement.<xref ref-type="bibr" rid="article-140572.r21">[21]</xref></p>
        <p>Patients might progress to a decreased level of consciousness, central hypoventilation requiring mechanical ventilation. On review of systems, it will be pertinent to ask for fever, weight loss, and night sweats will be essential to look for any B symptoms or paraneoplastic process. A complete neurological examination is vital to look for focal neurological deficits and rule out other possible causes of encephalitis.</p>
      </sec>
      <sec id="article-140572.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosing autoimmune encephalitis can be difficult as the average onset of symptoms to diagnosis often takes a few weeks to 3 months. Infectious encephalitis can be fatal and should always be eliminated from one&#x02019;s differential before considering AIE. Even after eliminating other potential causes, the diagnosis of AIE is not easy. To diagnose autoimmune encephalitis, we need multiple tools to aid in the diagnosis, although clinical judgment is the key to making decisions. They will include a constellation of neuropsychiatric symptoms, lab studies, neuroimaging, and electroencephalogram. Therefore, a group of experts came to a consensus to help clinicians identify the disorder to initiate appropriate treatment.&#x000a0;</p>
        <p>The following criteria were adopted for evaluation of&#x000a0;possible diagnosis of autoimmune encephalitis:</p>
        <list list-type="bullet">
          <list-item>
            <p>Subacute onset (usually within a few weeks but less than 3 months) with change in the level of consciousness or personality; limbic system involvement including working memory deficits, lethargy, or psychiatric manifestations. At least 1 of the following:
<list list-type="bullet"><list-item><p>New focal clinical central nervous system findings</p></list-item><list-item><p>Seizures not explained by a previously diagnosed seizure disorder</p></list-item><list-item><p>CSF pleocytosis (&#x0003e;5 white blood cells per mm<sup>3</sup>)</p></list-item><list-item><p>Magnetic resonance imaging (MRI) brain findings suggestive of encephalitis</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>&#x000a0; &#x000a0; &#x000a0; Reasonable exclusion of possible alternative causes*&#x000a0;<xref ref-type="bibr" rid="article-140572.r22">[22]</xref></p>
          </list-item>
        </list>
        <p>All 3 criteria must be met.</p>
        <p>#MRI brain increased signal on T2 weighted fluid-attenuated inversion recovery (FLAIR) sequence images seen in one or both medial temporal lobes (limbic encephalitis) or multifocal areas involving grey or white matter compatible with demyelination or inflammation.&#x000a0;</p>
        <p>Definite diagnosis of autoimmune limbic encephalitis-</p>
        <list list-type="bullet">
          <list-item>
            <p>Subacute onset of symptoms (&#x0003c;3 months) involving the limbic system area (memory deficits, neuropsychiatric symptoms, or seizures)</p>
          </list-item>
          <list-item>
            <p>MRI brain is suggestive of abnormality highly restricted to bilateral medial temporal lobes on T2 weighted FLAIR&#x000a0;images</p>
          </list-item>
          <list-item>
            <p>One of the following is present:
<list list-type="bullet"><list-item><p>CSF pleocytosis (&#x0003e;5 white blood cells per mm<sup>3</sup>)</p></list-item><list-item><p>Electroencephalogram is suggestive of slow-wave or epileptic activity corresponding to temporal lobes</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Reasonable exclusion of alternative causes*</p>
          </list-item>
        </list>
        <p>If all 4 criteria** match, the definitive diagnosis can be made.</p>
        <p>*Infectious meningoencephalitis, septic encephalopathy, metabolic encephalopathy, toxins, cerebrovascular disease, neoplasms, Creutzfeldt-Jakob disease, epileptic disorders, Hashimoto encephalopathy, autoimmune disorders, mitochondrial/metabolic storage disorders.</p>
        <p>**If 1 of the first 3 criteria does not match, a diagnosis of definite limbic encephalitis can be made only in the presence of antibodies against cell-surface, synaptic, or onconeural proteins. Antibodies should be detected both in sera and CSF fluid for diagnosis.</p>
        <p>Results from studies have shown that out of all patients with NMDAR encephalitis with antibodies detected in CSF, 14% of cases were found to have no detectable antibodies in serum.&#x000a0;Therefore, collection of both CSF and serum is recommended to detect antibodies. Antibody titers may correlate with clinical severity in CSF studies and, to a lesser extent, with serum, but determining the clinical recovery based on titers remains controversial. Moreover, the clinical picture and associated comorbidities are considered relatively reliable for evaluating the clinical course, treatment response, and overall prognosis.<xref ref-type="bibr" rid="article-140572.r23">[23]</xref></p>
        <p>Following&#x000a0;diagnosis, screening for the presence of neoplasm is necessary. There is a correlation between coexisting neoplasm with a clinical subtype of antibody detection. The best initial step is to undergo a CT scan of the chest, abdomen, and pelvis to look for pulmonary, abdominal, or urogenital malignancies. Females should undergo gynecological exams with breast and ovarian ultrasound/magnetic resonance imaging based on sensitivity and clinical judgment. Similarly, males should undergo testicular ultrasound as a part of the urological evaluation. If the above imaging does not yield any findings, a whole-body 18F-Fluorodeoxyglucose (FDG)-PET should be considered.</p>
      </sec>
      <sec id="article-140572.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The treatment options for autoimmune encephalitis include immunosuppression and tumor resection, if applicable. The treatment regimen is based on principles of autoimmune disease management with the aim of pathogenic antibody depletion. It is important to note that treatment should not be delayed until detection of the antibody, as early initiation is associated with improved outcomes. A&#x000a0;multidisciplinary&#x000a0;team should be involved in the team involving neurologists, rheumatologists, and oncologists to manage AIE. First-line therapy for AIE includes corticosteroids (1 g intravenous methylprednisolone for 3&#x000a0;to 5 days), intravenous immunoglobulins (0.4 g/kg/day for 5 days), and plasmapheresis alone or combined.</p>
        <p>Plasmapheresis should be considered in the treatment when patients have severe dysautonomia, refractory seizures, or central hypoventilation syndrome. Second-line immunotherapy should be considered for patients who fail to improve on these regimens. This includes rituximab (375 mg/m<sup>2</sup> for 4 weeks) and cyclophosphamide (750 mg/m<sup>2</sup> for 6 months) alone or combined in the adult population. Nonetheless, if underlying malignancy were found, it should undergo removal or chemotherapy as it accelerates improvement and prevents relapses.<xref ref-type="bibr" rid="article-140572.r4">[4]</xref></p>
      </sec>
      <sec id="article-140572.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Due to its variable presentation, it could mimic other clinical conditions, and therefore, other differentials should be considered. Most patients develop additional syndrome features within days or a few weeks. Due to the initial prodrome of fever and headache, infectious causes of meningoencephalitis must be ruled out. It progresses with behavior changes, so clinicians should consider toxic and metabolic encephalopathy in these scenarios. Patients can present with focal neurological deficits, so cerebrovascular accidents should be higher in the differentials. These patients should undergo a thorough physical examination in conjunction with neuroimaging for diagnosis. Intracranial space-occupying lesions are a possible cause of seizure or behavior disturbances.<xref ref-type="bibr" rid="article-140572.r24">[24]</xref></p>
        <p>Some autoimmune encephalitides have early and prominent psychiatric manifestations, leading to admission to an inpatient psychiatric unit. Clinicians should focus on the clinical progression of the disease as these patients develop additional features of the syndrome within days to a few weeks. Careful examination may reveal subtle neurologic deficits that should lead to the consideration of autoimmune encephalitis. Patients may present with a demyelinating disorder (eg, multiple sclerosis) or autoimmune (lupus, neurosarcoidosis) that have multi-system involvement and should be appropriately evaluated with CSF studies and neuroimaging. Neurodegenerative diseases like Alzheimer dementia usually have chronic onset and should be further evaluated with neuroimaging. Rarely, inherited and metabolic disorders can cause neuropsychiatric manifestations with a positive family history that needs further study.</p>
      </sec>
      <sec id="article-140572.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>As mentioned above, usually, autoimmune encephalitis is treatment-responsive with immunosuppression and tumor removal, although staging of the cancer is independently associated with adverse outcomes. According to an observational cohort study, 94% received first-line therapy with immunosuppression or tumor removal that resulted in improvement within four weeks (53%), with most of them having good outcomes in the first 24 months. These outcomes continue to improve up to 18 months from symptom onset. Predictors of good outcomes were associated with early treatment and not requiring intensive care unit admission.<xref ref-type="bibr" rid="article-140572.r4">[4]</xref>&#x000a0;Patients need to be followed closely after recovery to look for relapse. As per the recommendations, surveillance imaging at 4 to 6-month intervals for at least 4 years is suggested. Overall, cell-surface antibodies have a better prognosis than those associated with intracellular antibodies.</p>
      </sec>
      <sec id="article-140572.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Although autoimmune encephalitis is often treatment-responsive, it can lead to serious complications if left untreated or if there is a delay in treatment. This includes cognitive impairment, sleep disorders, hyperkinesia, autonomic dysfunction, persistent amnesia (anti-leucine-rich-glioma-inactivated 1 encephalitis), coma, and status epilepticus. According to a retrospective study by Xu et al, central hypoventilation syndrome is a key risk factor for mechanical ventilation during hospitalization in anti-NMDAR encephalitis patients and, therefore, needs to be monitored closely.<xref ref-type="bibr" rid="article-140572.r25">[25]</xref></p>
      </sec>
      <sec id="article-140572.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education is necessary to understand the etiology, acute and chronic clinical progression of the condition, and its strong association with underlying malignancy. They should be educated about the variable course of the disease, which may lead to a delay in diagnosis. Furthermore, patients should be encouraged to follow up after hospital discharge with their respective neurologist /oncologist due to concerns about&#x000a0;relapse and screening for malignancy.</p>
        <p>These patients should undergo imaging every 6 months for at least 4 years to look for any growth of tumor or metastasis, which might not be evident early and can lead to neurological manifestations. Families should be involved in the process of healthcare decision-making whenever possible as they may notice unusual changes in the patient's behavior or possible seizures. Moreover, patients should be educated about the side effects of chronic therapy with steroids and the role of immunosuppressive treatment, which may put them at risk of infection or systemic side effects.</p>
      </sec>
      <sec id="article-140572.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An eclectic clinical presentation encompasses autoimmune encephalitis with varying disease progression levels that require the expertise of multiple specialists. Healthcare professionals tasked with the management of AIE need to be well-informed about the condition to ensure that the patient receives the most appropriate care. The management of autoimmune encephalitis is complex and requires expert opinion under a neurologist, rheumatologist, internist, oncologist, oncosurgeon, and pharmacist, all functioning as a cohesive, interprofessional team. Once the patient has made significant improvement,&#x000a0;they should receive appropriate follow-up for complete recovery, potential side effects of immunotherapy, and tumor screening secondary to AIE. With proper management, the patient should be able to make a full recovery and maintain a state of remission.</p>
      </sec>
      <sec id="article-140572.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140572&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140572">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/neurology/autoimmune-encephalitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=140572">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140572/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140572">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-140572.s15">
        <title>References</title>
        <ref id="article-140572.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000e9;bert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Muccilli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wennberg</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Tang-Wai</surname>
                <given-names>DF</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Encephalitis and Autoantibodies: A Review of Clinical Implications.</article-title>
            <source>J Appl Lab Med</source>
            <year>2022</year>
            <month>Jan</month>
            <day>05</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>81</fpage>
            <page-range>81-98</page-range>
            <pub-id pub-id-type="pmid">34996085</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanniah</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Subramaniam</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Anti-NMDA Receptor Encephalitis: A Challenge in Psychiatric Settings.</article-title>
            <source>J Psychiatr Pract</source>
            <year>2022</year>
            <month>Jan</month>
            <day>06</day>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>78</fpage>
            <page-range>78-83</page-range>
            <pub-id pub-id-type="pmid">34989350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Sanderson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Hart</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Easton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kneen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Beeching</surname>
                <given-names>NJ</given-names>
              </name>
              <collab>National Encephalitis Guidelines Development and Stakeholder Groups</collab>
            </person-group>
            <article-title>Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines.</article-title>
            <source>J Infect</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>64</volume>
            <issue>4</issue>
            <fpage>347</fpage>
            <page-range>347-73</page-range>
            <pub-id pub-id-type="pmid">22120595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gabilondo</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Armangu&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Honig</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Benseler</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Kawachi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Martinez-Hernandez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gresa-Arribas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ryan-Florance</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Torrents</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Balice-Gordon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.</article-title>
            <source>Lancet Neurol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-65</page-range>
            <pub-id pub-id-type="pmid">23290630</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armangue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Spatola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vlagea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mattozzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>C&#x000e1;rceles-Cordon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinez-Heras</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Llufriu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Muchart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Erro</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Abraira</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moris</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Monros-Gim&#x000e9;nez</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Corral-Corral</surname>
                <given-names>&#x000cd;</given-names>
              </name>
              <name>
                <surname>Montejo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Toledo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bataller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Secondi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ari&#x000f1;o</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Hern&#x000e1;ndez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Juan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marcos</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Alsina</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <collab>Spanish Herpes Simplex Encephalitis Study Group</collab>
            </person-group>
            <article-title>Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis.</article-title>
            <source>Lancet Neurol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>760</fpage>
            <page-range>760-772</page-range>
            <pub-id pub-id-type="pmid">30049614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cabezudo-Garc&#x000ed;a</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mena-V&#x000e1;zquez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Estivill Torr&#x000fa;s</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Serrano-Castro</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Response to immunotherapy in anti-IgLON5 disease: A systematic review.</article-title>
            <source>Acta Neurol Scand</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>141</volume>
            <issue>4</issue>
            <fpage>263</fpage>
            <page-range>263-270</page-range>
            <pub-id pub-id-type="pmid">31853949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Diwani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Handel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pollak</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leite</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lennox</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Okai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Manohar</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data.</article-title>
            <source>Lancet Psychiatry</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>235</fpage>
            <page-range>235-246</page-range>
            <pub-id pub-id-type="pmid">30765329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ari&#x000f1;o</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Armangu&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petit-Pedrol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sabater</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martinez-Hernandez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Aug</month>
            <day>23</day>
            <volume>87</volume>
            <issue>8</issue>
            <fpage>759</fpage>
            <page-range>759-65</page-range>
            <pub-id pub-id-type="pmid">27466467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Sonderen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thijs</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Coenders</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Jiskoot</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Sanchez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Bruijn</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>van Coevorden-Hameete</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Schreurs</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Sillevis Smitt</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Oct</month>
            <day>04</day>
            <volume>87</volume>
            <issue>14</issue>
            <fpage>1449</fpage>
            <page-range>1449-1456</page-range>
            <pub-id pub-id-type="pmid">27590293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Sonderen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ari&#x000f1;o</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Petit-Pedrol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>K&#x000f6;rtv&#x000e9;lyessy</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wandinger</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wirtz</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Schreurs</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Sillevis Smitt</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>The clinical spectrum of Caspr2 antibody-associated disease.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Aug</month>
            <day>02</day>
            <volume>87</volume>
            <issue>5</issue>
            <fpage>521</fpage>
            <page-range>521-8</page-range>
            <pub-id pub-id-type="pmid">27371488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Pettingill</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kleopa</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Schiza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mazia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zuliani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Morvan syndrome: clinical and serological observations in 29 cases.</article-title>
            <source>Ann Neurol</source>
            <year>2012</year>
            <month>Aug</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>241</fpage>
            <page-range>241-55</page-range>
            <pub-id pub-id-type="pmid">22473710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spatola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Petit-Pedrol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Simabukuro</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Armangue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Barcelo Artigues</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Juli&#x000e0; Benique</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gorman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Felipe</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capar&#x000f3; Oblitas</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Investigations in GABA<sub>A</sub> receptor antibody-associated encephalitis.</article-title>
            <source>Neurology</source>
            <year>2017</year>
            <month>Mar</month>
            <day>14</day>
            <volume>88</volume>
            <issue>11</issue>
            <fpage>1012</fpage>
            <page-range>1012-1020</page-range>
            <pub-id pub-id-type="pmid">28202703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petit-Pedrol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Armangue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bataller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cellucci</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Martinez-Hernandez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mason</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Kruer</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Ritacco</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Grisold</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Meaney</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Alcal&#x000e1;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sillevis-Smitt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Balice-Gordon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.</article-title>
            <source>Lancet Neurol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>276</fpage>
            <page-range>276-86</page-range>
            <pub-id pub-id-type="pmid">24462240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lancaster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Constantinescu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raizer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Skeen</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Grisold</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ohta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Guzman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Balice-Gordon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen.</article-title>
            <source>Lancet Neurol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-76</page-range>
            <pub-id pub-id-type="pmid">19962348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laurido-Soto</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Brier</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>McCullough</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bucelli</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Patient characteristics and outcome associations in AMPA receptor encephalitis.</article-title>
            <source>J Neurol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>266</volume>
            <issue>2</issue>
            <fpage>450</fpage>
            <page-range>450-460</page-range>
            <pub-id pub-id-type="pmid">30560455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tobin</surname>
                <given-names>WO</given-names>
              </name>
              <name>
                <surname>Lennon</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Komorowski</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Probst</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Clardy</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Aksamit</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Appendino</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Lucchinetti</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Pittock</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Sandroni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tippmann-Peikert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wirrell</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>McKeon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients.</article-title>
            <source>Neurology</source>
            <year>2014</year>
            <month>Nov</month>
            <day>11</day>
            <volume>83</volume>
            <issue>20</issue>
            <fpage>1797</fpage>
            <page-range>1797-803</page-range>
            <pub-id pub-id-type="pmid">25320100</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carvajal-Gonz&#x000e1;lez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leite</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Woodhall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coutinho</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Balint</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pettingill</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carr</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sheerin</surname>
                <given-names>UM</given-names>
              </name>
              <name>
                <surname>Press</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Press</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lunn</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maddison</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Meinck</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Vandenberghe</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes.</article-title>
            <source>Brain</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>137</volume>
            <issue>Pt 8</issue>
            <fpage>2178</fpage>
            <page-range>2178-92</page-range>
            <pub-id pub-id-type="pmid">24951641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamid</surname>
                <given-names>SHM</given-names>
              </name>
              <name>
                <surname>Whittam</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saviour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alorainy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mutch</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Linaker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bhojak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Woodhall</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Appleton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Duddy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease.</article-title>
            <source>JAMA Neurol</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-71</page-range>
            <pub-id pub-id-type="pmid">29131884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gresa-Arribas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Planagum&#x000e0;</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Petit-Pedrol</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawachi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Katada</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Simabukuro</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Armangu&#x000e9;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Hern&#x000e1;ndez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Human neurexin-3&#x003b1; antibodies associate with encephalitis and alter synapse development.</article-title>
            <source>Neurology</source>
            <year>2016</year>
            <month>Jun</month>
            <day>14</day>
            <volume>86</volume>
            <issue>24</issue>
            <fpage>2235</fpage>
            <page-range>2235-42</page-range>
            <pub-id pub-id-type="pmid">27170573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Compta</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Neurological profiles beyond the sleep disorder in patients with anti-IgLON5 disease.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>493</fpage>
            <page-range>493-499</page-range>
            <pub-id pub-id-type="pmid">30694925</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Restrepo-Mart&#x000ed;nez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Espinola-Nadurille</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>L&#x000f3;pez-Hern&#x000e1;ndez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>T&#x000e9;llez-Mart&#x000ed;nez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bustamante-G&#x000f3;mez</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Bautista-G&#x000f3;mez</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bayliss</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ram&#x000ed;rez-Berm&#x000fa;dez</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Neuropsychiatric aspects of anti-NMDA receptor encephalitis].</article-title>
            <source>Rev Alerg Mex</source>
            <year>2021</year>
            <season>Oct-Dec</season>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>251</fpage>
            <page-range>251-263</page-range>
            <pub-id pub-id-type="pmid">34904561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Balu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benseler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bien</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Cellucci</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cortese</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Dale</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Geschwind</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Glaser</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Honnorat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>H&#x000f6;ftberger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Iizuka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Irani</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Lancaster</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pr&#x000fc;ss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rae-Grant</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reindl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Rost&#x000e1;sy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saiz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Venkatesan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wandinger</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A clinical approach to diagnosis of autoimmune encephalitis.</article-title>
            <source>Lancet Neurol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>391</fpage>
            <page-range>391-404</page-range>
            <pub-id pub-id-type="pmid">26906964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gresa-Arribas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Torrents</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Aguilar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McCracken</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gleichman</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Balice-Gordon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.</article-title>
            <source>Lancet Neurol</source>
            <year>2014</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-77</page-range>
            <pub-id pub-id-type="pmid">24360484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berkowitz</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Approach to Neurologic Infections.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2021</year>
            <month>Aug</month>
            <day>01</day>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>818</fpage>
            <page-range>818-835</page-range>
            <pub-id pub-id-type="pmid">34623094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140572.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Central Hypoventilation Is a Key Risk Factor for Mechanical Ventilation During the Acute Phase of Anti-N-Methyl-D-Aspartate Receptor Encephalitis.</article-title>
            <source>Front Neurol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>728594</fpage>
            <pub-id pub-id-type="pmid">34795627</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
